2026 Year in Review

Mr. Stembaum joined BofA in 2009 in Brazil and relocated to New York in 2015 to focus on MedTech. Over the last 16 years, Bruno has done extensive work with both private and publicly listed firms on M&A transactions, equity and debt financing.

Ms. Begley joined BofA in 2024 and has 5+ years of experience working in the MedTech industry, including at GE Healthcare and Integra LifeSciences. Ms. Begley received a BS in Bioengineering from Lehigh University, an MEng in Biomedical Engineering from Cornell University, and an MBA from the Tuck School of Business at Dartmouth College.

Ibraheem (Ib) leverages his expertise in smart materials and biomaterials to support the medical device sector. From 2010 to 2013, Ib was a Research Fellow at Global Surgery Group of Johnson & Johnson, where he led external and front-end innovation and intellectual property for Ethicon Biosurgery. From 2006 to 2010, he was the Director of Applied Research & New Technology Assessment of novel biomaterials. Before that, he was Chief Scientist at Closure Medical Corp (acquired by J&J in 2005).

Roger is a co-founder and a Managing Partner of Mass General Brigham Ventures and Vice President, Mass General Brigham. He joined Mass General Brigham Ventures at its founding in 2008 and played a significant role in the creation, early sourcing, financing, and development of the portfolio which includes 55 companies since inception and over $450 million in assets under management. Roger also leads the intellectual property and business development and licensing teams across Mass General Brigham that are responsible for commercialization from the over $2 billion in annual research across the system.

David manages a consulting firm that provides emerging businesses with strategic financial leadership. He is an active member of the screening and due diligence committees of Beacon Angels, TBD Angels, and Mass Medical Angels. As a contributor to the ongoing development of Greater Boston's entrepreneurial ecosystem. David has been an Adjunct Instructor of Finance at Northeastern University for the past eight years, teaching Entrepreneurial Finance. He is a licensed Certified Public Accountant (CPA).

Jen is a Partner in the Accounting Advisory practice, focused on building CrossCountry’s expertise and market presence in the biotechnology industry. She works collaboratively with clients at emerging growth companies, helping them prepare for strategic transactions (IPO, M&A, etc.) and supports them in the post-transaction environment. Jen has extensive technical accounting experience and helps clients account for complex agreements and transactions, as well as significant experience helping public and venture-backed companies through times of change, including establishing and optimizing processes, training people, and selecting technology. Jen has led teams through IPOs, carve-outs, and strategic FinOps projects (such as accelerating close timelines, establishing SOX controls, and selecting and integrating systems).